Psoralidin / IL18 Cancer Research Results

PSO, Psoralidin: Click to Expand ⟱
Features:
Psoralidin is a prenylated coumestan isolated primarily from Psoralea corylifolia (Babchi). It is not a classical anticancer drug.
Psoralidin generally acts to suppress oncogenic signaling and survival pathways while promoting apoptosis in tumor cells.
Reported effects (context-dependent, preclinical):
-DOWNREGULATES pro-survival pathways (e.g., NF-κB, STAT3)
-UPREGULATES apoptotic signaling (caspase activation)
-MODULATES androgen receptor signaling in prostate cancer models
-SENSITIZES tumor cells to chemo- and radio-induced stress

This positions psoralidin as a biologic modulator, not a driver.

Across cancer cell and animal models, psoralidin has been associated with:
-Apoptosis induction
  -Caspase activation
  -Mitochondrial depolarization
-Inflammatory pathway suppression
  -NF-κB inhibition
  -STAT3 attenuation
-Hormone signaling modulation
  -Androgen receptor suppression (prostate cancer context)
-Oxidative stress interaction
  -Redox imbalance tipping tumor cells toward death under stress

Psoralidin is best described as chemopreventive or chemo-sensitizing, not chemoprotective


IL18, Interleukin 18: Click to Expand ⟱
Source:
Type:
High levels of IL-18 production may play a major role in the growth and metastasis of renal cancer. Higher expression of IL-18 is detected in various cancer cells.

IL-18 is often expressed in various cancers, including melanoma, colorectal cancer, breast cancer, and gastric cancer. Its expression can vary depending on the tumor type and the immune context. Elevated levels of IL-18 are frequently associated with the presence of tumor-infiltrating immune cells and can be produced by both immune and tumor cells.

High levels of IL-18 expression are often associated with a favorable prognosis in various cancers. Elevated IL-18 levels in the tumor microenvironment can correlate with increased immune cell infiltration and better overall survival.
Scientific Papers found: Click to Expand⟱
4966- PSO,    Psoralidin induces pyroptosis in both tumor cells and macrophages as well as enhances nature killer cell cytotoxicity to suppress hepatocellular carcinoma
- vitro+vivo, HCC, HepG2
Pyro↑, TumCG↓, mt-ROS↑, Casp3↑, cl‑GSDME↑, IL1β↑, IL18↑, NK cell↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

mt-ROS↑, 1,  

Cell Death ⓘ

Casp3↑, 1,   cl‑GSDME↑, 1,   Pyro↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL18↑, 1,   IL1β↑, 1,   NK cell↑, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IL18, Interleukin 18
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:389  Target#:369  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page